Want to see BCAX full AI Analyst Report?

Bicara Therapeutics Inc. (BCAX) Price & Analysis

80 Followers

BCAX Stock Chart & Stats

$24.01

-$0.31(-1.97%)

At close: Jan 08 4:00 PM EST

$24.01

-$0.31(-1.97%)

Day’s Range― - ―

52-Week Range$8.74 - $29.90

Previous CloseN/A

Volume80.52K

Average Volume (3M)589.95K

Market Cap

$1.90B

Enterprise Value$933.53M

Total Cash (Recent Filing)$539.75M

Total Debt (Recent Filing)$1.44M

Price to Earnings (P/E)―

Beta1.44

Next Earnings

Aug 18, 2026

EPS Estimate

-0.82

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.78

Shares Outstanding65,703,865

10 Day Avg. Volume641,254

30 Day Avg. Volume589,947

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)2.29

Price to Sales (P/S)0.00

P/FCF Ratio-8.59

Enterprise Value/Market Cap0.49

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-5.95

Forecast

1Y Price Target

$32.11

Price Target Upside33.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-3.41

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet And RunwayA sizeable cash position and runway into H1 2029 materially reduce near‑term financing risk and enable completion of pivotal FORTIFI‑HN01, the alternative dosing study and prelaunch investments. This funding stability supports execution of clinical and commercial milestones over the next 2–3 years.

Durable Clinical Efficacy SignalsSustained, deep responses and multi‑year survival signals indicate potential best‑in‑class efficacy and a strong therapeutic profile. Durable clinical outcomes strengthen regulatory arguments, support premium positioning in head‑and‑neck indications and underpin longer‑term commercial differentiation.

Defined Pivotal Pathway & MilestonesA clear Phase III plan with a targeted interim for accelerated approval concentrates development risk into defined milestones. This reduces execution ambiguity, allows prioritized resource allocation, and provides predictable inflection points for regulatory progress and commercial planning over the coming 12–24 months.

Bears Say

Pre‑revenue, Widening LossesConsistent pre‑revenue status and materially widening losses signal persistent negative economics until commercialization or partnering. Ongoing operating deficits and heavy cash burn increase reliance on capital markets or partnerships and raise dilution or financing timing risks if trial timelines slip.

Commercial Transition Increases SpendPlanned prelaunch hires, market‑access build and higher manufacturing costs will structurally raise SG&A and R&D spend. Higher fixed operating costs mean sustained elevated cash burn even after pivotal readouts, pressuring margins and necessitating disciplined capital allocation or further funding through commercialization.

Data Maturity & Regulatory/design UncertaintySmall cohort sizes and relatively immature follow‑up increase regulatory and interpretive risk for label claims. A randomized dosing study without a formal non‑inferiority margin and evolving competitor trial sizes raise the probability of additional studies, delayed approvals, or constrained label claims, affecting long‑term market access.

Bicara Therapeutics Inc. News

Bicara Therapeutics Holds 2026 Annual Stockholder Meeting

Bicara Therapeutics Inc. ( ($BCAX) ) has issued an update. On June 9, 2026, Bicara Therapeutics Inc. held...

22d ago

BCAX

Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Bicara Therapeutics Inc.,...

1M ago

BCAX

Bicara Highlights Durable Three-Year Data for Ficerafusp Alfa

The latest announcement is out from Bicara Therapeutics Inc. ( ($BCAX) ). On May 21, 2026, Bicara Therapeutics...

1M ago

BCAX

Bicara Therapeutics management to meet with Cantor

Meeting to be held in New York on May 26 hosted by Cantor. Published first on TheFly –...

1M ago

BCAX

Bicara Therapeutics Highlights Momentum in Earnings Call

Bicara Therapeutics Inc. (($BCAX)) has held its Q1 earnings call. Read on for the main highlights of the...

1M ago

BCAX

Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum

Bicara Therapeutics Inc. (($BCAX)) has held its Q1 earnings call. Read on for the main highlights of the...

1M ago

BCAX

BCAX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Bicara Therapeutics Inc. (BCAX) is scheduled to report 1st quarter earnings on 05/19/2026, before the market opens. Regarding...

2M ago

BCAX

Bicara Therapeutics’ Acquisition Strategy Poses Operational, Financing, and Shareholder Dilution Risks

Bicara Therapeutics Inc. (BCAX) has disclosed a new risk, in the Accounting & Financial Operations category. Bicara Therapeutics...

2M ago

BCAX

Bicara Therapeutics price target raised to $37 from $36 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Bicara Therapeutics (BCAX) to $37 from $36 and keeps an...

2M ago

BCAX

Bicara Therapeutics price target raised to $18 from $16 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Bicara Therapeutics (BCAX) to $18 from $16 and keeps a...

2M ago

BCAX

Bicara Therapeutics reports Q1 EPS (93c), consensus (65c)

“The first quarter of 2026 reflects strong progress as we work to position ficerafusp alfa as the cornerstone...

2M ago

BCAX

Tyler Van Buren Reiterates Buy Rating on Ficera, Citing Strong Phase III Momentum and Best-in-Class Potential in HPV-Negative Head and Neck Cancer

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on BCAX stock, giving a Buy rating...

2M ago

BCAX

Bicara Therapeutics initiated with a Buy at Guggenheim

Guggenheim last night initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $42 price target With...

2M ago

BCAX

Bicara Therapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $42 price target Published first on...

2M ago

BCAX

BCAX FAQ

What was Bicara Therapeutics Inc.’s price range in the past 12 months?

Bicara Therapeutics Inc. lowest stock price was $8.74 and its highest was $29.90 in the past 12 months.

What is Bicara Therapeutics Inc.’s market cap?

Bicara Therapeutics Inc.’s market cap is $1.90B.

When is Bicara Therapeutics Inc.’s upcoming earnings report date?

Bicara Therapeutics Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 47 days.

How were Bicara Therapeutics Inc.’s earnings last quarter?

Bicara Therapeutics Inc. released its earnings results on May 11, 2026. The company reported -$0.93 earnings per share for the quarter, missing the consensus estimate of -$0.649 by -$0.281.

Is Bicara Therapeutics Inc. overvalued?

According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bicara Therapeutics Inc. pay dividends?

Bicara Therapeutics Inc. does not currently pay dividends.

What is Bicara Therapeutics Inc.’s EPS estimate?

Bicara Therapeutics Inc.’s EPS estimate is -0.82.

How many shares outstanding does Bicara Therapeutics Inc. have?

Bicara Therapeutics Inc. has 65,703,865 shares outstanding.

What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?

Bicara Therapeutics Inc. reported an EPS of -$0.93 in its last earnings report, missing expectations of -$0.649. Following the earnings report the stock price went up 1.506%.

Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?

Currently, no hedge funds are holding shares in BCAX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bicara Therapeutics Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-35.89%

Trailing 12-Months

Asset Growth

15.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Bicara Therapeutics Inc. (BCAX) Earnings & Revenues

Historic Earnings Reports

BCAX Company Deck

BCAX Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong positive clinical momentum for ficera (deep, durable responses, peer-reviewed publication, planned pivotal interim in mid-2027 and upcoming 3‑year ASCO data), meaningful commercial and organizational build-out, and a bolstered balance sheet providing runway into H1 2029. Offsetting risks include rising operating expenses, limited size/maturity of some cohorts, regulatory/design considerations for the alternative dosing study, and competitive/expansion challenges in tough indications like CRC. On balance, the highlights — notably compelling clinical efficacy signals and secured funding — substantially outweigh the lowlights, but key open milestones (ASCO updates, interim analysis, alternative dosing readout) remain important near‑term catalysts and risks.View all BCAX earnings summaries

BCAX Stock 12 Month Forecast

Average Price Target

$32.11

▲(33.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","47":"$47","17.75":"$17.75","27.5":"$27.5","37.25":"$37.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.111111111111114,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,17.75,27.5,37.25,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.62,22.572307692307692,24.524615384615387,26.47692307692308,28.42923076923077,30.38153846153846,32.33384615384615,34.28615384615385,36.238461538461536,38.190769230769234,40.14307692307692,42.09538461538462,44.04769230769231,{"y":46,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.62,21.503931623931624,22.387863247863248,23.271794871794874,24.155726495726498,25.03965811965812,25.923589743589744,26.807521367521367,27.691452991452994,28.575384615384618,29.45931623931624,30.343247863247868,31.22717948717949,{"y":32.111111111111114,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.62,20.264615384615386,19.90923076923077,19.553846153846155,19.19846153846154,18.843076923076925,18.487692307692306,18.13230769230769,17.776923076923076,17.42153846153846,17.066153846153846,16.71076923076923,16.355384615384615,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.67,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.62,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >